Back to UBS Group AG UBS Group AG

GANXGANX
22 quarters

Position history for UBS Group AGUBS Group AG's holdings in GAIN THERAPEUTICS INC

Yes. Ubs holds 215,012 shares of GANX (Gain Therapeutics), worth $436,475, as of its Q2 2026 13F filing. It reduced the position by 5,477 shares (-2.5%) from Q1 2026. Ubs has held GANX since Q1 2021, across 22 quarterly 13F filings.

Current Value

$436,475

Current Shares

215,012

Total Value Change

+$345,475

Total Shares Change

+208,907

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
215,012
-2.5%
$436,4750.0%$2.03
0
2026-Q1
Increased
220,489
+171.8%
$427,7490.0%$2.63
39
2025-Q4
Decreased
81,121
-42.3%
$261,2100.0%$3.05
0
2025-Q3
Increased
140,677
+331.1%
$248,9980.0%$1.81
25
2025-Q2
Decreased
32,635
-24.7%
$58,7430.0%$1.97
0
2025-Q1
Increased
43,360
+23.1%
$82,8180.0%$1.89
18
2024-Q4
Increased
35,227
+316.6%
$76,0900.0%$2.18
23
2024-Q3
Decreased
8,455
-26.0%
$15,0500.0%$1.99
0
2024-Q2
Increased
11,422
+31.7%
$14,6200.0%$1.28
16
2024-Q1
Decreased
8,673
-38.1%
$32,6970.0%$3.77
0
2023-Q4
Increased
14,023
+68.9%
$45,7860.0%$3.27
21
2023-Q3
Decreased
8,304
-12.1%
$27,2370.0%$3.28
0
2023-Q2
Increased
9,447
+119.4%
$42,3220.0%$4.50
22
2023-Q1
Decreased
4,305
-40.9%
$20,7500.0%$4.71
0
2022-Q4
Increased
7,289
+76.8%
$22,8150.0%$3.13
20
2022-Q3
Decreased
4,122
-35.7%
$13,0000.0%$3.17
0
2022-Q2
Increased
6,411
+56.4%
$23,0000.0%$3.59
18
2022-Q1
Decreased
4,100
-60.9%
$17,0000.0%$4.09
0
2021-Q4
Increased
10,497
+55.7%
$57,0000.0%$5.30
20
2021-Q3
Increased
6,740
+64.4%
$51,0000.0%$7.65
20
2021-Q2
Decreased
4,100
-32.8%
$41,0000.0%$10.20
0
2021-Q1
New
6,105
-
$91,0000.0%$14.66
33

Other major holders of GANX: GREENLIGHT CAPITAL INC, Gotham Asset Management, LLC, MARSHALL WACE, LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used